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Introduction: The infusion of 2 partially HLA-matched um-
bilical cord blood (UCB) is a potential strategy for extending
UCB transplantation to more patients. The risk and beneﬁts
of double UCB transplantation (dUCBT) relative to those
observed after transplantation with related and unrelated
adult donors remains to be determined.
Methods: Two hundred and eighty three adult patients
undergoing ﬁrst allogeneic transplant for acute myeloid
leukemia (N¼166), acute lymphocytic leukemia (N¼87) and
myelodysplastic syndrome (N¼30) at Singapore General
Hospital (N¼176) and National University Cancer Institute,
Singapore (N¼107) between 2005-2013 were studied. The
patients received transplantation using matched related
donor (MRD, n¼172), matched unrelated donor (MUD,
n¼70) or 4-6/6 HLA matched dUCB (n¼41) graft after mye-
loablative conditioning (MAC, n¼147) or reduced intensity
conditioning (RIC, N¼136), consisting of ﬂudarabine, cyclo-
phosphamide (120 mg/kg for MAC , 50 mg/kg for RIC) and
total body irradiation (12-14 Gy for MAC, 2 Gy for RIC).
Results: The leukemia free survival at 5 years was similar for
each donor type, 43% for dUCB, 45% for MSD and 42% for
MUD (p¼0.26). There was no statistically signiﬁcant differ-
ence in relapse-related death and transplant-related mor-
tality among the 3 donor types. However, when the outcome
was analyzed separately according to conditioning regimen,
a signiﬁcant difference in survival was observed among
patients receiving RIC. As compared to the recipients of MSD
or MUD, the risk of relapse-related death was highest in
recipients of dUCB (HR 2.75, 95% CI 1.05-7.1; p¼0.04) after
RIC, resulting in the lowest overall survival (dUCB 9%; MSD
43%; MUD 29%; p¼0.009). For patients receiving MAC,
leukemia-free survival in patients after dUCBT (59%) was
comparable to that after MSD (46%) and MUD (52%) trans-
plantation (p¼0.82)
Conclusions: Our results support the use of 2 partially HLA-
matched UCB as a suitable alternative for patients without an
available HLA matched donor. However, the use of RIC for
dUCBT is still limited by high incidence of relapse. Future
studies are necessary to deﬁne the best regimen that can
induce sustained engraftment without increasing the risk of
relapse and regimen-related toxicity.382
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Introduction: In adult patients with high risk ALL, deﬁned as
Philadelphia cromosome ALL (Phi+) or slow response to
chemotherapy, sibling donor aHSCT in ﬁrst remission is
recommended as consolidation treatment after achieving a
complete remission. Still is unclear what other subgroup of
adult patients beneﬁt the most from aHSCT.
Objectives: The primary objective was to describe the clin-
ical outcomes of ALL patients after aHSCT in our center,
including overall survival (OS), relapse-free-survival (RFS)
and transplant-related-mortality (TRM) .
Results: Between 1994 and 2013, 37 patients with ALL were
transplanted, 16 Phi+ and 21 Phi-. Two patients had a second
transplant for relapsed ALL Phi+, therefore 39 aHSCT pro-
cedures for ALL have been performed in our center. The
average age is 33 yo (range: 17-56) and 68% were male pa-
tients (n¼25). Phi+ patients weremostly>30 yo (63%, n¼10),
as compared to Phi- that were mostly 30 yo (67%, n¼14).
Most transplants were performed in ﬁrst remission (70%,
n¼22), under myeloablative conditioning regimen in 92%
(n¼34). Reduced intensity conditioning (RIC) regimen was
used because of age (n¼1; Phi-) and relapse (n¼2; Phi+).
GVHD prophylaxis consisted of cyclosporin A and metho-
trexate in all the patients. Among Phi+ patients, 69% (n¼11)
had TKI prior to aHSCT. Only 25% (n¼4) received TKI as
maintenance therapy after aHSCT. Average CD34 dose
collected by leukapheresis was 5.5x106/kg (range:
2,14e9,16x106/kg), with mean platelet engraftment at day 15
after transplant (range: 8-25 days) and mean neutrophil
engraftment at day 16 after transplant (no ﬁlgrastim is used
after transplant) (range: 10-22 days). In Phi+ patients, 3-year
EFS and OS was 49% and 64%, respectively. In Phi- patients 3-
year EFS and OS was 40% and 43%, respectively. One year
TRMwas 14% in Phi- and 21% in Phi+ ALL patients. Univariate
analysis failed to show a correlation between RFS and OS
with pre and post aHSCT minimal residual disease as
measured bymulticolor ﬂow cytometry and PCR (in Phi+ ALL
patientes) or remission status (CR1 vs CR2).
Conclusions: Our data on the outcomes of ALL patients were
consistent with that reported in literature. In our series, OS in
Phi+ patients was superior to those with Phi-, we speculated
that it may be at least in part due to disease erradication by
TKI. Our data support our practice of offering aHSCT early in
the disease course for patients with ALL patients, specially
Ph+ ALL patients.383
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Background: Hematopoietic Stem Cell Transplantation
(HSCT) is a potentially curative treatment for a number of
hematological malignancies and hereditary disorders. How-
ever, patients undergoing HSCT may have serious compli-
cations that require support in an intensive care unit (ICU),
with signiﬁcant associated mortality and reported 6-month
overall survival (OS) less than 5%.
Patients and Methods: Retrospective study of adult patients
undergoing autologous, allogeneic and umbilical cord blood
HSCT between 2007 and 2011 who required ICU transfer at
